ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2310건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2100 | Completed | A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above | COVID-19 | Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Biological: Inactivated SARS-CoV-2 Vaccine (Vero cell) Biological: Placebo |
Phase 3 | China National Biotec Group Company Limited, G42 Healthcare company, Abu Dhabi Health Services Company, Wuhan Institute of Biological Products Co., Ltd, Beijing Institute of Biological Products Co Ltd. | INDUSTRY | 44101 | All | 18 Years | Bahrain International Exhibition & Convention Centre Affiliated to Salymynia Medical Complex S, Sanabis, Bahrain Katameya Medical Center, Cairo, Egypt Vacsera health Care facilities , MoH, Cairo, Egypt Prince Hamza Hospital, Amman, Jordan Sheikh Khalifa Medical City, SEHA, Abu Dhabi, United Arab Emirates Al Qarain Primary Health Care Centre-MOHAP, Sharjah, United Arab Emirates |
| 2099 | Unknown status | A Study to Evaluate the Efficacy, Safety and Immunogenicity of SARS-CoV-2 Vaccine (Vero Cells), Inactivated in Healthy Adults Aged 18 Years and Older (COVID-19) | COVID-19 | Biological: SARS-CoV-2 Vaccine (Vero Cells), Inactivated Biological: Placebo |
Phase 3 | Shenzhen Kangtai Biological Products Co., LTD, Beijing Minhai Biotechnology Co., Ltd | INDUSTRY | 28000 | All | 18 Years | |
| 2098 | Completed | A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19) | COVID-19 | Drug: IMU-838 Other: Placebo |
Phase 3 | Immunic AG, FGK Clinical Research GmbH | INDUSTRY | 223 | All | 18 Years | Military Medical Academy, Clinic of Infectious Diseases, Sofia, Bulgaria UMHATEM N.I.Pirogov, Clinic of internal diseases, Sofia, Bulgaria University Hospital Frankfurt, Infectious Diseases, Frankfurt, Germany Clinic of the Hannover Medical School, Pneumology Clinic, Hannover, Germany |
| 2097 | Withdrawn | A Study to Evaluate the Efficacy, Safety and Tolerability of PDNO Infusion in COVID-19 Patients With Acute Pulmonary Hypertension | COVID-19 | Drug: Sodium chloride (placebo) Drug: PDNO |
Phase 2 | Attgeno AB, Vinnova | INDUSTRY | 0 | All | 18 Years | Danderyd Hospital, Danderyd, Sweden Orebro University Hospital, Orebro, Sweden |
| 2096 | Recruiting | A Study to Evaluate the Efficacy, Safety, and Concentration of SNS812 in Mild to Moderate COVID-19 Patients | Mild to Moderate COVID-19 | Drug: MBS-COV Drug: Placebo |
Phase 2 | Oneness Biotech Co., Ltd. | INDUSTRY | 135 | All | 18 Years | Velocity Clinical Research, Salt Lake City, Utah, United States Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare, New Taipei City, Taiwan National Taiwan University Hospital, Taipei, Taiwan Taipei Medical University Hospital, Taipei, Taiwan Taipei Municipal Wanfang Hospital, Taipei, Taiwan |
| 2095 | Unknown status | A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine as a Booster Dose in Population Aged 12-17 Years | SARS-CoV-2 Infection | Biological: SCTV01E Biological: mRNA-1273 |
Phase 2 | Sinocelltech Ltd. | INDUSTRY | 300 | All | 12 Years ~ 17 Years | |
| 2094 | Not yet recruiting | A Study to Evaluate the Immunogenicity and Safety of A Recombinant Protein COVID-19 Vaccine as Booster Vaccines | SARS-CoV-2 Infection | Biological: SCTV01E-2 Biological: SCTV01E |
Phase 2 | Sinocelltech Ltd. | INDUSTRY | 600 | All | 3 Years |
